Abstract
Pauling's orthomolecular hypothesis appeared in 1968, stating that some forms of mental illness and disease are related to biochemical errors in the body. Vitamin therapy is believed to be a means of compensating for such errors. There have been few empirical studies on vitamin therapy in individuals with autism. This article presents a critical analysis of the 12 published studies located through an extensive computerized search. Studies were systematically evaluated to provide an objective assessment of empirical evidence supporting the efficacy of vitamin treatment. The majority of studies report a favorable response to vitamin treatment. However, interpretation of these positive findings needs to be tempered because of methodological shortcomings inherent in many of the studies. For example, a number of studies employed imprecise outcome measures, were based on small samples and possible repeat use of the same subjects in more than one study, did not adjust for regression effects in measuring improvement, and omitted collecting long-term follow-up data. Recommendations are offered to assist researchers in designing future investigations.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Barthelemy, C., Garreau, B., Leddet, I., Ernouf, D., Muh, J. P., & Lelord, G. (1981). Behavioral and biological effects of oral magnesium, vitamin B6 administration in autistic children.Magnesium-Bulletin, 2, 150–153.
Barthelemy, C., Garreau, B., Leddet, I., Sauvage, D., Domenech, J., Muh, J. P., & Lelord, G. (1980). Biological and clinical effects of oral magnesium and associated magnesium-vitamin B6 administration of certain disorders observed in infantile autism.Therapie, 35, 627–632.
Barthelemy, C., Garreau, B., Leddet, I., Sauvage, D., Muh, J. P., Lelord, G., & Callaway, E. (1983). Interest of behavioral scales and determination levels of urinary homovanillic acid for the control of the effects of a treatment associating vitamin B6 and magnesium in children presenting an autistic behavior.Neuropsychiatirie de l'Enfance, 31, 289–301.
Barthelemy, C., Martineau, J., Bruneau, N., Muh, J. P., Lelord, G., & Callaway, E. (1988). Clinical and biological effects of pyridoxine plus magnesium in autistic subjects. In J. E. Leklem & R. D. Reynolds (Eds.),Clinical and physiological applications of vitamin B-6 (pp. 329–356). New York: Alan R. Liss.
Bonisch, V. (1968). Experience with pyrithioxin in brain damaged children with autistic syndrome.Praxis der Kinderpsychologie, 8, 308–310.
Damasio, A., & Maurer, R. (1978). A neurological model for childhood autism.Archives of Neurology, 35, 778–796.
Garreau, B., Barthelemy, C., Domenech, J., Sauvage, D., Muh, J. P., Callaway, E., & Lelord, G. (1980). Troubles du metabolisme de la dopamine chez des enfants ayant un comportement autistique: Resultats des examens cliniques et des dosages urinaires de l'acide homovanilique (AHV).Acta Psychiatrica Belgium, 80, 240–265.
Gualtieri, C., Golden, R., & Fahs, J. (1983). New developments in pediatric psychopharmacology.Developmental and Behavioral Pediatrics, 3, 202–209.
Jacobson, N. S., & Truax, P. (1991). Clinical significance: A statistical approach to defining meaningful change in psychotherapy research.Journal of Consulting and Clinical Psychology, 59, 12–19.
Jonas, C., Etienne, T., Barthelemy, C., Jouve, J., & Mariotte, N. (1984). Clinical and biochemical advantage of associated vitamin B6 and magnesium in the treatment of infantile autism residual state, in adulthood.Therapie, 39, 37–52.
Kazdin, A. E. (1988).Child psychotherapy and behavior change (3rd ed., pp. 23–68). New York: Wiley.
Kazdin, A. E. (1993). Treatment of conduct disorder: Progress and directions in psychotherapy research.Development and Psychopathology, 5, 277–310.
Lelord, G., Callaway, E., Muh, J. P., Arlot, J. C., Sauvage, D., Garreau, B., & Domenech, J. (1978). Modifications in urinary homovanillic acid after ingestion of vitamin B6: Functional study in autistic children.Revue Neurologigue, 134, 797–801.
Lelord, G., Muh, J. P., Barthelemy, C., Martineau, J., & Garreau, B. (1981). Effects of pyridoxine and magnesium on autistic symptoms—initial observations.Journal of Autism and Developmental Disorders, 11, 219–230.
Lipsey, M. W. (1990).Design sensitivity: Statistical power for experimental research. Newbury Park, CA: Sage.
Martineau, J., Barthelemy, C., Cheliakine, C., & Lelord, G. (1988). Brief report: An open middle-term study of combined vitamin B6-magnesium in a subgroup of autistic children selected on their sensitivity to treatment.Journal of Autism and Developmental Disorders, 18, 435–447.
Martineau, J., Barthelemy, C., Garreau, B., & Lelord, G. (1985). Vitamin B6, magnesium, and combined B6-magnesium: Therapeutic effects in childhood autism.Biological Psychiatry, 20, 467–478.
Martineau, J., Barthelemy, C., & Lelord, G. (1986). Long-term effects of combined vitamin B6-magnesium administration in an autistic child.Biological Psychiatry, 21, 511–518.
Martineau, J., Barthelemy, C., Roux, S., Garreau, B., & Lelord, G. (1989). Electrophysiological effects of fenfluramine or combined vitamin B6 and magnesium on children with autistic behavior.Developmental Medicine and Child Neurology, 31, 721–727.
Martineau, J., Garreau, B., Barthelemy, C., Callaway, E., & Lelord, G. (1981). Effects of vitamin B6 on averaged evoked potentials in infantile autism.Biological Psychiatry, 16, 627–640.
Martineau, J., Garreau, B., Barthelemy, C., & Lelord, G. (1982). Comparative effects of oral B6Mg and Mg administration on evoked potentials conditioning in autistic children. In A. Rothenberger (Ed.),Event-related potentials in children (pp. 411–416). New York: Elsevier.
Morgan, S. (1986). Early childhood autism: Changing perspectives.Journal of Child and Adolescent Psychiatry, 3, 3–9.
Moore, R., & Bloom, F. (1978). Central catecholamine neuron systems: Anatomy and physiology of the norepinephrine and epinephrine systems.Annual Review of Neuroscience, 2, 129–169.
Muscettola, G., Wehr, T. A., & Goodwin, F. K. (1977). Effect of diet on urinary MHPG excretion in depressed patients and normal control subjects.American Journal of Psychiatry, 134, 914–916.
Naglieri, J. A., LeBuffe, P. A., & Pfeiffer, S. I. (1994).Devereux scales of mental disorders manual San Antonio, TX: Psychological Corp.
Pauling, L. (1968). Orthomolecular psychiatry.Science, 160, 265–271.
Pfeiffer, S. I. (1989). Follow-up of children and adolescents treated in psychiatric facilities: A methodology review.Psychiatric Hospital, 20(1), 15–20.
Pfeiffer, S. I. (1990). An analysis of methodology in follow-up studies of adult inpatient psychiatric treatment.Hospital and Community Psychiatry, 41, 1315–1321.
Pfeiffer, S. I., Soldivera, S., & Norton, J. (1992).A consumer's guide to mental health treatment outcome measures. Devon, PA: The Devereux Foundation.
Potter, W. Z., Hsiao, J. K., & Goldman, S. M. (1989). Effects of renal clearance on plasma concentrations of homovanillic acid.Archives of General Psychiatry, 46, 558–562.
Rimland, B., Callaway, E., & Dreyfus, P. (1978). The effects of high doses of vitamin B6 on autistic children.American Journal of Psychiatry, 135, 472–475.
Rosenthal, R. (1990). How are we doing in soft psychology?American Psychologist, 45, 775–777.
Rutter, M. (1991). Autism: Pathways from syndrome definition to pathogenesis.Comprehensive Mental Health Care, 1, 5–26.
Schafer, E., & MacKean, C. (1975). Evidence that monoamines influence human evoked potentials.Brain Research, 99, 49–58.
Small, J., Demyer, M., & Kendall, J. (1969). Experience with response averaging in autistic children.Electroencephalography and Clinical Neurophysiology, 26, 112–113.
Speer, D. C. (1992). Clinically significant change: Jacobson and Truax (1991) revisited.Journal of Consulting and Clinical Psychology, 60, 402–408.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Pfeiffer, S.I., Norton, J., Nelson, L. et al. Efficacy of vitamin B6 and magnesium in the treatment of autism: A methodology review and summary of outcomes. J Autism Dev Disord 25, 481–493 (1995). https://doi.org/10.1007/BF02178295
Issue Date:
DOI: https://doi.org/10.1007/BF02178295